Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.


Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Beenish Zulfiqar, MD |
It’s 11 a.m. on a Wednesday. You see a new patient in your fellow’s clinic with impressive physical findings, including a prominent skin rash and deforming arthritis. The patient has been to many doctors and is frustrated that her condition remains undiagnosed and untreated. You thoroughly examine the patient, present her case to your attending…

Didem Saygin, MD, Bethany Marston, MD, Nina Couette, DO, Sara Patrizi, DO, & Adam Kilian, MD |
Since the beginning of the pandemic, the ACR’s Committee on Training and Workforce (COTW) has been interested in better understanding how fellowship recruitment is affected by virtual recruitment from the perspectives of both program directors and trainees. This past year, the COTW conducted a survey study to gain the perspective of program directors.1 The Rheumatology…

Dana DiRenzo, MD, MHS |
The prescription is a powerful tool for a physician. As rheumatologists, we prescribe many things—drugs, physical therapy, durable medical equipment—but what about stress reduction? We are very specific about times of day to take medications and in what manner. Patients ask: With or without food? With other medications? Before or after other prescribed medications? If…

For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.

Elizabeth Hofheinz, MPH, MEd |
When it comes to systemic lupus erythematosus (SLE) and cardiovascular events (CVEs), the rheumatology community is woefully lacking in information, say researchers from the University of California, Los Angeles (UCLA) David Geffen School of Medicine and Cedars-Sinai Medical Center. Their recent work on biomarkers associated with an increased risk for cardiovascular events in women with…

Benjamin Aronow, MD, Eduardo Mantovani Cardoso, MD, Steffi Thomas, DO, Prashant Grover, MD, & Weishali Joshi, MD |
The COVID-19 pandemic has filled hospitals with patients with rapidly progressive respiratory failure and diffuse bilateral opacities on chest X-ray.1 Additionally, many patients with severe COVID-19 develop acute kidney injury and require dialysis.2 Pulmonary-renal syndromes are also important to consider in this setting. Although alveolar hemorrhage is a cardinal feature of this syndrome, many patients…

On Dec. 27, 2017, RaDonda Vaught killed Charlene Murphey, allegedly. Ms. Murphey was a lifelong resident of Gallatin, a suburb of Nashville, Tenn. She was well known from having worked at the local Walmart for 24 years, before she retired in 2012, when she was 65 years old.1 On Dec. 24, 2017, she was helping…

A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.